Supplying bath-mats, blankets , Rugs and other textile products to walmart, J.c Penny , Lidil- Hongkong
E-mart- korea , and to other 15 countries .
The company seems to be on a turnaround path, , recently
raised funds by issuing more than 15% equity on preferential basis,
Girik capital bought 7.17 lacs shares on 20th Jan
2017 , Girik capital is known to find deep value and turnaround stories.
Their commitment to the Faze3 can be seen from fact that the
founders Charandeep singh and Varun Daga have bought 2 lacs shares each on
personal capacity too .
Seems like a interesting story.
Doing more work and will update with a detailed analysis.
HUGE POSITIVE IN - Dec
16 Q3 Results
Sales almost flat yoy. 56.75 vs 55.59
Profits 35.91 Crore As compare to 69 lakhs in Dec 15 &
4.32 crores is Sept 16.
1)Other income of 17.45 crore , 12.38 crore part of the
other income is because of written back amount due to settlement with canara bank for
waiver of unapplied interest and other charges on the working capital loan
given to its subsidiary.
2) Further 11.12 crore deferred tax assets written back due
to which profits swelled to 35.91 crore.
Other than the implications of the above nos there is
operational efficiency seen.
Cost of material consumer came down by 9 crores , other
expenses reduces by 4.3 crores
Interset payment reduced by 1.71 crores.
A clear 7.34 crore of profits is due to operational efficiency.
The total outstanding on the FCCB bonds was 103 crores, due
the the settlement with the bond holders
61.28 crore is written back in the books.
Other liabilities reduced from 161 crores to 27 crore
Company have mentioned in the notes that Due to the equity
issued in oct 2016 and write backs the companys net worth have become positive
to the amount of 75.89 crores and the
company have come out of BIFR with effect from 1 dec 2016.
This seems to be curious case of a big time financial restructuring
and operational improvement.
For more clarifications Please read the detailed note by the
company in the result fillings.

No comments:
Post a Comment